Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$192,420 Mln
Revenue (TTM)
$63,922 Mln
Net Profit (TTM)
$0 Mln
ROE
0.4 %
ROCE
21.8 %
P/E Ratio
11.1
P/B Ratio
4
Industry P/E
26.75
EV/EBITDA
8.4
Div. Yield
4.2 %
Debt to Equity
--
Book Value
$--
EPS
$6.9
Face value
--
Shares outstanding
2,516,389,888
CFO
$117,929.00 Mln
EBITDA
$115,983.00 Mln
Net Profit
$75,684.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
| -24.8 | -5.5 | -9.9 | -41.9 | -6.1 | -0.4 | 2.7 |
|
BSE Sensex*
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P 100
| -1.1 | 9.8 | -4.0 | 15.3 | 16.3 | 16.9 | 11.9 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
| -8.7 | -1.7 | 44.8 | 1.9 | -7.1 | 22.4 | 39.9 |
|
S&P 100
| 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 | -5.8 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
|
74.8 | 192,420.1 | 63,922.0 | 17,434.0 | 26.3 | 78.3 | 11.1 | 4.0 |
| 181.7 | 332,084.3 | 57,367.0 | 4,195.0 | 14.9 | 138.9 | 80.7 | 220.7 | |
| 271.7 | 145,422.7 | 34,126.0 | 5,933.0 | 24.2 | 86.4 | 24.6 | 23.4 | |
| 123.7 | 17,637.6 | 9,704.5 | 1,479.3 | 16.7 | 8.9 | 11.9 | 1.1 | |
| 45.8 | 94,814.3 | 47,636.0 | 5,419.0 | 17.1 | 31.3 | 17.4 | 5.5 | |
| 152.0 | 35,422.1 | 222,286.0 | 1,558.0 | 1.0 | -- | 23.2 | 16.1 | |
| 733.3 | 669,764.9 | 49,003.2 | 11,106.4 | 22.7 | 74 | 60.6 | 42.5 | |
| 100.3 | 129,255.9 | 28,730.0 | 5,965.0 | 20.5 | 31.8 | 21.8 | 6.3 | |
| 149.6 | 357,157.9 | 89,331.0 | 21,810.0 | 30.7 | 29.4 | 16.5 | 4.6 | |
| 22.6 | 130,024.4 | 62,463.0 | 7,866.0 | 15.5 | 8.7 | 16.6 | 1.4 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care,... cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. Address: 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 Read more
Chairman, President & CEO
Mr. Robert M. Davis J.D.
Chairman, President & CEO
Mr. Robert M. Davis J.D.
Headquarters
Rahway, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Merck & Company Inc (MRK) stood at 0 as on 31-Mar-25
The share price of Merck & Company Inc (MRK) is $74.80 (NYSE) as of 15-May-2025 16:18 EDT. Merck & Company Inc (MRK) has given a return of -6.12% in the last 3 years.
Merck & Company Inc (MRK) has a market capitalisation of $ 192,420 Mln as on 15-May-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Merck & Company Inc (MRK) is 3.98 times as on 15-May-2025, a 21% discount to its peers’ median range of 5.04 times.
The P/E ratio of Merck & Company Inc (MRK) is 11.13 times as on 15-May-2025, a 58% discount to its peers’ median range of 26.75 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Merck & Company Inc (MRK) and enter the required number of quantities and click on buy to purchase the shares of Merck & Company Inc (MRK).
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. Address: 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
The CEO & director of Mr. Robert M. Davis J.D.. is Merck & Company Inc (MRK), and CFO & Sr. VP is Mr. Robert M. Davis J.D..
There is no promoter pledging in Merck & Company Inc (MRK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
73,766
|
|
|
37,294
|
|
|
35,109
|
|
|
15,059
|
|
|
13,492
|
|
|
12,800
|
|
|
10,188
|
|
|
3,672
|
|
|
1,810
|
| Merck & Company Inc (MRK) | Ratios |
|---|---|
|
Return on equity(%)
|
78.3
|
|
Operating margin(%)
|
26.27
|
|
Net Margin(%)
|
27.27
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Merck & Company Inc (MRK) was $0 Mln.
$1.33
(
